Bimekizumab Treatment Impact on Pain and Fatigue in Patients with Active Psoriatic Arthritis Who Were Biologic DMARD- Naive or Had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3 Studies

被引：0

作者：

Husni, M. Elaine ^{[1
]}

Mease, Philip J. ^{[2
,3
]}

Merola, Joseph ^{[4
]}

Behrens, Frank

Favalli, Ennio G. ^{[5
,6
,7
]}

McGonagle, Dennis ^{[8
]}

Tillett, William R. ^{[9
]}

Tsuji, Shigeyoshi ^{[10
]}

Ink, Barbara ^{[11
]}

Bajracharya, Rajan ^{[11
]}

Lambert, Jeremy ^{[12
]}

Coarse, Jason ^{[13
]}

Gossec, Laure ^{[14
,15
]}

机构：

[1] Cleveland Clin, Dept Rheumat & Immunol Dis, Cleveland, OH USA

[2] Swedish Med Center, Providence St Joseph Hlth, Seattle, WA USA

[3] Univ Washington, Sch Med, Seattle, WA USA

[4] Harvard Med Sch, Brigham & Womens Hosp, Newton, MA USA

[5] Goethe Univ, Univ Hosp, Div Rheumatol, Frankfurt, Germany

[6] Fraunhofer Inst Translat Med Pharmacol, Frankfurt, Germany

[7] Univ Milan, ASST Gaetano Pini CTO, Dept Rheumatol, Milan, Italy

[8] Univ Leeds, Leeds Biomed Res Ctr, Leeds, England

[9] Royal Natl Hosp Rheumat Dis, Dept Rheumatol, Bath, England

[10] Nippon Life Hosp, Osaka, Japan

[11] UCB Pharma, Slough, England

[12] UCB Pharma, Irigny, France

[13] UCB Pharma, Morrisville, NY USA

[14] Sorbonne Univ, Paris, France

[15] Hop La Pitie Salpetriere, Paris, France

来源：

ARTHRITIS & RHEUMATOLOGY | 2023年 / 75卷

关键词：

PHASE-3; TRIAL; DOUBLE-BLIND;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

0527

引用

页码：1035 / 1038

页数：4

共 50 条

[1] Bimekizumab Impact on Health-Related Quality of Life and Physical Function in Patients with Active Psoriatic Arthritis Who Were Biologic DMARD-Naive or Had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3, Randomized Studies
Gladman, Dafna
Gossec, Laure
Husni, M. Elaine
Erik, Lars
Gisondi, Paolo
Gottlieb, Alice B.
Thaci, Diamant
Ink, Barbara
Bajracharya, Rajan
Lambert, Jeremy
Lyris, Nikos
Coarse, Jason
Tillett, William R.
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4452 - 4456
[2] Bimekizumab Treatment Impact on Work Productivity in Biologic DMARD-Naive and TNFi-IR Patients with Active Psoriatic Arthritis: Results up to 1 Year from Two Phase 3 Studies
Mease, Philip J.
Gladman, Dafna
Gossec, Laure
Nash, Peter
Ink, Barbara
Coarse, Jason
Lyris, Nikos
Willems, Damon
Tillett, William R.
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2774 - 2777
[3] Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Psoriatic Arthritis and Inadequate Response or Intolerance to TNF-α Inhibitors Who Were Responders at Week 16: Results from a Phase 3, Randomized Study
Tillett, William R.
Merola, Joseph
Tanaka, Yoshiya
Favalli, Ennio G.
McGonagle, Dennis
Thaci, Diamant
Walsh, Jessica A.
Ink, Barbara
Bajracharya, Rajan
Coarse, Jason
Ritchlin, Christopher T.
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4459 - 4461
[4] BIMEKIZUMAB EFFICACY AND SAFETY IN BIOLOGIC DMARD- NAIVE PATIENTS WITH PSORIATIC ARTHRITIS WAS CONSISTENT WITH OR WITHOUT METHOTREXATE: 52-WEEK RESULTS FROM THE PHASE 3 ACTIVE-REFERENCE STUDY BE OPTIMAL
Mcinnes, I.
Mease, P. J.
Tanaka, Y.
Behrens, F.
Gossec, L.
Husni, M. E.
Kristensen, L. E.
Warren, R. B.
Ink, B.
Bajracharya, R.
Coarse, J.
Eells, J.
Gottlieb, A. B.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1133 - 1134
[5] Bimekizumab Treatment Results in Improvements in Fatigue and Pain in Biologic DMARD-Naive or TNFi-IR Patients with Active Psoriatic Arthritis: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
Husni, M. Elaine
Mease, Philip J.
Merola, Joseph
Behrens, Frank
Favalli, Ennio Giulio
McGonagle, Dennis
Tillett, William
Tsuji, Shigeyoshi
Ink, Barbara
Assudani, Deepak
Bajracharya, Rajan
Coarse, Jason
Lambert, Jeremy
Gossec, Laure
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4197 - 4199
[6] Improvement from ixekizumab treatment in patients with psoriatic arthritis who have had an inadequate response to one or two TNF inhibitors
Kirkham, Bruce
Sesin, Carlos
Gellett, Amanda M.
Sprabery, Aubrey T.
Lin, Chen-Yen
Turkiewicz, Anthony
RHEUMATOLOGY, 2021, 60 (09) : 4367 - 4372
[7] Effect of bimekizumab on patient-reported disease impact in patients with psoriatic arthritis: 1-year results from two phase 3 studies
Gossec, Laure
Orbai, Ana-Maria
de Wit, Maarten
Coates, Laura C.
Ogdie, Alexis
Ink, Barbara
Coarse, Jason
Lambert, Jeremy
Taieb, Vanessa
Gladman, Dafna D.
RHEUMATOLOGY, 2024,
[8] BIMEKIZUMAB TREATMENT RESULTED IN IMPROVEMENTS IN FATIGUE AND PAIN IN BIOLOGIC DMARD-NAIVE OR TNFI-IR PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: POOLED 16-WEEK RESULTS FROM TWO PHASE 3 RANDOMISED, PLACEBO-CONTROLLED STUDIES
Rischmueller, Maureen
Husni, M. Elaine
Mease, Philip J.
Merola, Joseph F.
Behrens, Frank
Favalli, Ennio G.
McGonagle, Dennis
Tillett, William
Tsuji, Shigeyoshi
Ink, Barbara
Assudani, Deepak
Bajracharya, Rajan
Coarse, Jason
Lambert, Jeremy
Gossec, Laure
INTERNAL MEDICINE JOURNAL, 2023, 53 : 26 - 26
[9] Impact of Upadacitinib on Reducing Pain in Patients With Active Psoriatic Arthritis: Results From Two Phase 3 Trials in Patients With Inadequate Response to Non-biologic or Biologic DMARDs
Bessette, Louis
Tillett, William
Mease, Philip
de Vlam, Kurt
Lippe, Ralph
Maniccia, Anna
Zueger, Patrick
Feng, Dai
Kato, Koji
Ostor, Andrew
McInnes, Iain
JOURNAL OF RHEUMATOLOGY, 2021, 48 (07) : 1168 - 1168
[10] IMPACT OF UPADACITINIB ON REDUCING PAIN IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM TWO PHASE 3 TRIALS IN PATIENTS WITH INADEQUATE RESPONSE TO NON-BIOLOGIC OR BIOLOGIC DMARDs
Mcinnes, I.
Tillett, W.
Mease, P. J.
De Vlam, K.
Bessette, L.
Lippe, R.
Maniccia, A.
Zueger, P.
Feng, D.
Kato, K.
Ostor, A.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 800 - 801

← 1 2 3 4 5 →